J.A. Lieberman

6.8k total citations · 2 hit papers
50 papers, 5.2k citations indexed

About

J.A. Lieberman is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, J.A. Lieberman has authored 50 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Psychiatry and Mental health, 14 papers in Cellular and Molecular Neuroscience and 9 papers in Molecular Biology. Recurrent topics in J.A. Lieberman's work include Schizophrenia research and treatment (24 papers), Neurotransmitter Receptor Influence on Behavior (10 papers) and Treatment of Major Depression (8 papers). J.A. Lieberman is often cited by papers focused on Schizophrenia research and treatment (24 papers), Neurotransmitter Receptor Influence on Behavior (10 papers) and Treatment of Major Depression (8 papers). J.A. Lieberman collaborates with scholars based in United States, United Kingdom and Japan. J.A. Lieberman's co-authors include G E Duncan, Seiya Miyamoto, Brian P. Marx, John M. Kane, Miranda Chakos, Diana O. Perkins, Richard S.E. Keefe, Margaret G. Woerner, Daniel W. Bradford and Elaine Hoffman and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Neuroscience.

In The Last Decade

J.A. Lieberman

48 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

2004 749 citations Seiya Miyamoto, G E Duncan et al. Molecular Psychiatry profile →
The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis

1999 536 citations Richard S.E. Keefe, Diana O. Perkins et al. Schizophrenia Bulletin profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.A. Lieberman United States	29	3.2k	1.4k	952	882	738	50	5.2k
Bruce J. Kinon United States	47	5.0k 1.6×	1.3k 0.9×	882 0.9×	871 1.0×	789 1.1×	153	7.4k
Herbert Y. Meltzer United States	40	3.2k 1.0×	1.8k 1.3×	697 0.7×	1.1k 1.3×	493 0.7×	60	5.9k
Daniël P. van Kammen United States	51	3.6k 1.1×	2.1k 1.5×	1.7k 1.8×	1.4k 1.6×	607 0.8×	218	7.6k
Alan I. Green United States	42	3.4k 1.1×	1.5k 1.1×	1.8k 1.9×	599 0.7×	532 0.7×	100	7.0k
D. Pickar United States	33	1.9k 0.6×	1.6k 1.2×	915 1.0×	686 0.8×	271 0.4×	89	4.5k
David Pickar United States	44	2.5k 0.8×	2.1k 1.5×	1.3k 1.4×	859 1.0×	309 0.4×	135	6.5k
Birte Glenthøj Denmark	44	3.6k 1.1×	1.5k 1.1×	2.5k 2.6×	963 1.1×	495 0.7×	242	7.1k
Lyn S. Pilowsky United Kingdom	38	2.0k 0.6×	1.5k 1.1×	1.2k 1.3×	646 0.7×	242 0.3×	125	4.1k
S.R. Hirsch United Kingdom	28	2.1k 0.6×	804 0.6×	1.2k 1.2×	562 0.6×	435 0.6×	73	4.1k
Daniel Umbricht Switzerland	38	2.4k 0.7×	1.2k 0.8×	2.5k 2.6×	816 0.9×	673 0.9×	106	5.8k

Countries citing papers authored by J.A. Lieberman

Since Specialization

Citations

This map shows the geographic impact of J.A. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.A. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.A. Lieberman more than expected).

Fields of papers citing papers by J.A. Lieberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.A. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.A. Lieberman. The network helps show where J.A. Lieberman may publish in the future.

Co-authorship network of co-authors of J.A. Lieberman

This figure shows the co-authorship network connecting the top 25 collaborators of J.A. Lieberman. A scholar is included among the top collaborators of J.A. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.A. Lieberman. J.A. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brandl, Eva J., Tristram A. Lett, Nabilah I. Chowdhury, et al.. (2016). The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophrenia Research. 176(2-3). 131–135. 25 indexed citations

Tucker, Eric S., Gloria Haskell, Thomas M. Maynard, et al.. (2006). Limited influence of olanzapine on adult forebrain neural precursors in vitro. Neuroscience. 140(1). 111–122. 11 indexed citations

Miyamoto, Seiya, G E Duncan, Brian P. Marx, & J.A. Lieberman. (2004). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 10(1). 79–104. 749 indexed citations breakdown →

Marder, S.R., Susan M. Essock, Alexander L. Miller, et al.. (2002). The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophrenia Bulletin. 28(1). 5–16. 95 indexed citations

Chakos, Miranda, J.A. Lieberman, Elaine Hoffman, Daniel W. Bradford, & Brian Sheitman. (2001). Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. American Journal of Psychiatry. 158(4). 518–526. 484 indexed citations

Maynard, Thomas M., Linmarie Sikich, J.A. Lieberman, & Anthony‐Samuel LaMantia. (2001). Neural Development, Cell-Cell Signaling, and the "Two-Hit" Hypothesis of Schizophrenia. Schizophrenia Bulletin. 27(3). 457–476. 285 indexed citations

Jarskog, L. Fredrik, et al.. (2000). Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry. 48(7). 641–650. 140 indexed citations

Overstreet, David H., et al.. (2000). Enduring effects of prenatal cocaine administration on emotional behavior in rats. Physiology & Behavior. 70(1-2). 149–156. 64 indexed citations

Lieberman, J.A.. (1999). Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective. Biological Psychiatry. 46(6). 729–739. 362 indexed citations

10.

Tarazi, Frank I., Miranda Chakos, Houwei Wu, et al.. (1999). Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sciences. 64(18). 1595–1602. 24 indexed citations

11.

Keefe, Richard S.E., et al.. (1999). The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis. Schizophrenia Bulletin. 25(2). 201–222. 536 indexed citations breakdown →

12.

Chakos, Miranda, et al.. (1998). Striatal enlargement in rats chronically treated with neuroleptic. Biological Psychiatry. 44(8). 675–684. 90 indexed citations

13.

Woerner, Margaret G., José Alvir, Bruce L. Saltz, J.A. Lieberman, & John M. Kane. (1998). Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors. American Journal of Psychiatry. 155(11). 1521–1528. 173 indexed citations

14.

Lieberman, J.A., Richard B. Mailman, Gary H. Duncan, et al.. (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biological Psychiatry. 44(11). 1099–1117. 159 indexed citations

15.

Volkow, Nora D., Joanna S. Fowler, Jean Logan, et al.. (1997). Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. American Journal of Psychiatry. 154(1). 50–55. 145 indexed citations

16.

Lieberman, J.A.. (1997). Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity. Neuropsychopharmacology. 17(4). 205–229. 266 indexed citations

17.

Seeman, Philip, Carla Ulpian, Guy Chouinard, et al.. (1994). Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: No association with Schizophrenia. American Journal of Medical Genetics. 54(4). 384–390. 59 indexed citations

18.

Lieberman, J.A.. (1993). Time Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia. Archives of General Psychiatry. 50(5). 369–369. 363 indexed citations

19.

Bogerts, B., J.A. Lieberman, Robert M. Bilder, et al.. (1992). A VOLUMETRIC MRI STUDY OF LIMBIC STRUCTURES IN CHRONIC SCHIZOPHRENIA - RELATIONSHIP TO PSYCHOPATHOLOGY. Clinical Neuropharmacology. 15. 112A–113A. 4 indexed citations

20.

Kane, John M., Margaret G. Woerner, Michael Borenstein, James T. Wegner, & J.A. Lieberman. (1986). Integrating incidence and prevalence of tardive dyskinesia.. PubMed. 22(1). 254–8. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact